Valneva grabs flu vax approval in Japan; China to supply encephalitis jab to India in U-turn decision;

> Valneva has won approval for its EB66-based prototype influenza vaccine in Japan. Report

> China has flip-flopped on an earlier decision, agreeing to provide India with additional supplies of Japanese encephalitis vaccine for expansion of the Indian government's immunization program. Report

> GeoVax ($GOVX) has appointed Immunovaccine veteran Randal Chase to its board of directors. Release

> Measles vaccination must be scaled up in Ebola-affected countries, the World Health Organization says. More

> Immunovaccine has started a Phase II clinical trial of its DPX-Survivac cancer vaccine in recurrent lymphoma. Release

> Medigene has kicked off a Phase I/II study with DC Vaccine in patients with acute myeloid leukaemia. Release

And Finally... GIV Mobile is partnering up with the International Aids Vaccine Initiative (IAVI) to help fund R&D. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.